Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth.
Click here to learn more ›
Exit Survey of Women With Hypoactive Sexual Desire Disorder Treated With Bremelanotide in the RECONNECT Studies Demonstrated Meaningful Treatment Benefits
